UK markets open in 4 hours 43 minutes
NIKKEI 225
36,959.63 -1,120.07 (-2.94%) HANG SENG
16,176.25 -209.62 (-1.28%) CRUDE OIL
85.12 +2.39 (+2.89%) GOLD FUTURES
2,424.10 +26.10 (+1.09%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
49,022.61 -784.10 (-1.57%)
Almirall, S.A. (0O9B.IL)
IOB - IOB Delayed price. Currency in EUR
Add to watchlist
At close: 05:58PM BST
| Previous close | 8.10 |
| Open | 0.00 |
| Bid | 7.99 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 47,580 |
| Market cap | 1.859B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.18 (2.03%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Investing.com
Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).
© 2024 Yahoo. All rights reserved.